FDA May Push Boundaries To Speed REMS Negotiations

Law360, New York (July 5, 2017, 3:11 PM EDT) -- The U.S. Food and Drug Administration is reevaluating how it can "lift barriers" to generic competition in an effort to reduce drug prices. As part of this initiative, new FDA Commissioner Dr. Scott Gottlieb has made several strong public statements, including in congressional testimony, that signal an interest in exploring the limits of the agency's authority to curb purported abuses of the risk evaluation and mitigation strategies (REMS) program. The agency is holding a public meeting on July 18 to solicit input on the appropriate balance between innovation and access.

For years, the Food and Drug Administration and the generic drug industry...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Read the full article

Already a subscriber? Click here to login

US Sections

Global Sections

FDA May Push Boundaries To Speed REMS Negotiations

Stay ahead of the curve

Related Sections

Government Agencies

Beta

Show all interests